Alto Neuroscience, Inc. (ANRO)

USD 3.64

(-3.96%)

Operating Expenses Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual operating expenses in 2023 was 37.8 Million USD , up 29.76% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly operating expenses in 2024 Q1 was 14.28 Million USD , up 22.41% from previous quarter.
  • Alto Neuroscience, Inc. reported a annual operating expenses of 28.85 Million USD in annual operating expenses 2022, up 138.02% from previous year.
  • Alto Neuroscience, Inc. reported a annual operating expenses of 12.12 Million USD in annual operating expenses 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported a quarterly operating expenses of 18.24 Million USD for 2024 Q2, up 28.36% from previous quarter.
  • Alto Neuroscience, Inc. reported a quarterly operating expenses of 9.02 Million USD for 2023 Q2, up 26.84% from previous quarter.

Annual Operating Expenses Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual Operating Expenses of Alto Neuroscience, Inc. (2023 - 2021)

Year Operating Expenses Operating Expenses Growth
2023 37.8 Million USD 29.76%
2022 28.85 Million USD 138.02%
2021 12.12 Million USD 0.0%

Peer Operating Expenses Comparison of Alto Neuroscience, Inc.

Name Operating Expenses Operating Expenses Difference
ADC Therapeutics SA 233.01 Million USD 83.774%
Annovis Bio, Inc. 45.03 Million USD 16.045%
Biohaven Pharmaceutical Holding Company Ltd. 436.05 Million USD 91.329%
Ginkgo Bioworks Holdings, Inc. 1.1 Billion USD 96.589%
Nuvation Bio Inc. 99.82 Million USD 62.124%
Nuvation Bio Inc. 99.82 Million USD 62.124%
Arcus Biosciences, Inc. 457 Million USD 91.727%
Theriva Biologics, Inc. 21.43 Million USD -76.422%
Zymeworks Inc. 196.76 Million USD 80.784%